StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Heron Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Heron Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -7.2%. For fiscal 2025 it was -1.6%, against -8.0% the year before. The highest annual figure on record is -1.6% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1.6%+6.4
FY2024Dec 31, 2024-8.0%+79.1
FY2023Dec 31, 2023-87.1%+75.1
FY2022Dec 31, 2022-162.2%+90.1
FY2021Dec 31, 2021-252.3%+5.1
FY2020Dec 31, 2020-257.4%−113.1
FY2019Dec 31, 2019-144.3%+93.1
FY2018Dec 31, 2018-237.4%+394.9
FY2017Dec 31, 2017-632.4%+12730.8
FY2016Dec 31, 2016-13363.2%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-5.4%−1.0
Q1 FY2026Mar 31, 2026-13.7%−21.8
Q4 FY2025Dec 31, 20250.1%−10.1
Q3 FY2025Sep 30, 2025-10.7%+2.9
Q2 FY2025Jun 30, 2025-4.4%+13.5
Q1 FY2025Mar 31, 20258.1%+21.9
Q4 FY2024Dec 31, 202410.2%+40.1
Q3 FY2024Sep 30, 2024-13.6%+65.7
Q2 FY2024Jun 30, 2024-17.9%+115.6
Q1 FY2024Mar 31, 2024-13.8%+97.8
Q4 FY2023Dec 31, 2023-29.9%+37.9
Q3 FY2023Sep 30, 2023-79.3%+78.4
Q2 FY2023Jun 30, 2023-133.5%+45.6
Q1 FY2023Mar 31, 2023-111.6%+156.6
Q4 FY2022Dec 31, 2022-67.8%+191.4
Q3 FY2022Sep 30, 2022-157.7%+64.9
Q2 FY2022Jun 30, 2022-179.1%+90.3
Q1 FY2022Mar 31, 2022-268.2%−7.9
Q4 FY2021Dec 31, 2021-259.2%+38.3
Q3 FY2021Sep 30, 2021-222.6%+69.8
Q2 FY2021Jun 30, 2021-269.4%−23.5
Q1 FY2021Mar 31, 2021-260.3%−52.7
Q4 FY2020Dec 31, 2020-297.5%−128.3
Q3 FY2020Sep 30, 2020-292.4%−210.7
Q2 FY2020Jun 30, 2020-245.9%−104.7
Q1 FY2020Mar 31, 2020-207.6%−2.9
Q4 FY2019Dec 31, 2019-169.2%+8.7
Q3 FY2019Sep 30, 2019-81.8%+129.4
Q2 FY2019Jun 30, 2019-141.2%+83.6
Q1 FY2019Mar 31, 2019-204.7%+244.7
Q4 FY2018Dec 31, 2018-177.9%+437.7
Q3 FY2018Sep 30, 2018-211.2%+270.8
Q2 FY2018Jun 30, 2018-224.9%+269.3
Q1 FY2018Mar 31, 2018-449.5%+907.9
Q4 FY2017Dec 31, 2017-615.6%+3043.7
Q3 FY2017Sep 30, 2017-482.0%–
Q2 FY2017Jun 30, 2017-494.2%–
Q1 FY2017Mar 31, 2017-1357.4%–
Q4 FY2016Dec 31, 2016-3659.3%–

More Heron Therapeutics figures

See a number that looks wrong?